All fields are required.

Close Appointment form

Board of Directors

Improving patient outcomes with innovative drug therapies.

Lisa Colleran


Lisa Colleran has served as a Director on our Board since March 2018.

Ms. Colleran is the Principal of LNC Advisors, a strategic consulting firm that specializes in assisting biotech, pharmaceutical and medical device companies. She also currently serves on the Board of Directors for Establishment Labs and Ariste Medical.

Prior to founding LNC Advisors, Ms. Colleran served as Chief Executive Officer of LifeCell Corporation and a Board Member for Centaur Guerney, the holding company for LifeCell Corporation. From 2013 to 2018, Ms. Colleran also served as the Global President of LifeCell Corporation. Prior to assuming the role of Global President, Ms. Colleran served in numerous other roles at LifeCell, enhancing her expertise in marketing, business development and commercial operations. Before joining LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare in the Renal Division and her last position there was Vice President and General Manager of Renal Pharmaceuticals.

Ms. Colleran received her BSN from Molloy College and her MBA from Loyola University of Chicago.

John Cooper


John Cooper has served as a Director on our Board and Chair of the Audit Committee since September 2017.

Mr. Cooper’s career spans over 30 years of senior executive experience managing publicly-traded companies in the life sciences industry. He has played key leadership roles building companies with transformational medical technologies, including the first FDA approved synthetic peptide-containing pulmonary surfactant for premature infants with severe respiratory disease and the second FDA approved blood diagnostic test for HIV. Mr. Cooper has significant experience in corporate and organization development, raising capital, mergers and acquisitions, strategic alliances, investor relations, and corporate governance. Over his career, Mr. Cooper has raised approximately $1 billion in capital through various financing and strategic transactions. Currently, Mr. Cooper provides corporate development and financial advisory services to emerging public and private companies in the life sciences industry.

Mr. Cooper held executive leadership positions for Windtree Therapeutics (formerly Discovery Laboratories), a specialty biopharmaceutical company focused on respiratory therapeutics, from 2001 to 2016. His roles included President, Chief Executive Officer and Member of the Board of Directors, President and Chief Financial Officer, Executive Vice President and Chief Financial Officer. Prior to Discovery Labs, Mr. Cooper served as Senior Vice President and Chief Financial Officer at Chrysalis International Corporation (acquired by Phoenix Life Sciences) and its predecessor DNX Corporation, where he managed its initial public offering and negotiated and integrated several strategic acquisitions. Previously, Mr. Cooper served in senior financial management and executive committee roles at ENI Diagnostics (acquired by Pharmacia AB).

Mr. Cooper received his B.S. in Commerce from Rider University and holds a CPA designation.

Russell H. Ellison, MD, MSc


Dr. Ellison has served as a Director on our Board since January 2020.

Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, Inc., which focused on, among other indications, kidney fibrosis, and successfully completed the company’s strategic sale in December 2018; President and CEO of Bond Biosciences, Inc., a biotech start up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors, LLC a global investment banking boutique serving companies in the life sciences industry; Chairman and CEO of Assembly Biosciences, Inc. (formerly, Ventrus Biosciences, Inc.); Executive Vice President of Paramount Biosciences LLC, Vice President of Clinical Development at FibroGen, Inc. where he played a key role in the completion of a phase 2 trial with a HIF-PH inhibitor in anemia for Chronic Kidney Disease (CKD) patients; Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, Inc.; and Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche, Inc.

Dr. Ellison previously served as an Independent Board Director for several private and public companies including, Cougar Biotechnology Inc., ProSanos Corporation, Cormedix Inc., a cardio-renal clinical stage company, and Mt. Cook, a urology-focused company.

Dr. Ellison received an MSc from The London School of Tropical Medicine and Hygiene, and an MD from the University of British Columbia.

John P. McLaughlin


Mr. McLaughlin served as Chief Executive Officer of PDL BioPharma, Inc, from December 2008 until December 2018. Prior to joining PDL, he was the Chief Executive Officer and a Director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly traded biopharmaceutical company, from January 2000 to June 2008. From December 1997 to September 1999, Mr. McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr. McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President & General Counsel. From January 1985 to September 1987, Mr. McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law and has served as counsel to various subcommittees of the United States House of Representatives, where he drafted several measures that later became law.

Mr. McLaughlin has been a Director of PDL since 2008. He also serves on the Board of Directors of Lensar, Inc., a private medical technology company that develops and commercializes femtosec lasers for the treatment of cataracts, and Noden Pharma, a private company that commercializes two hypertension drugs worldwide. Lensar, Inc. and Noden Pharma are primarily owned by PDL. Mr. McLaughlin co-founded and served as Chairman of the Board of Eyetech Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, which was subsequently acquired by OSI Pharmaceuticals, Inc.; co-founded and served as a Director of Peak Surgical, Inc., a private medical device company, until it was acquired by Medtronic in 2011; served as a director of AxoGen, Inc., a publicly traded biopharmaceutical company until 2014; served as a director of Adverum Biotechnologies, Inc., a publicly traded biopharmaceutical company, until 2016; and served as a director of Seattle Genetics, Inc., a publicly traded biopharmaceutical company, until 2016.

Mr. McLaughlin received a B.A. from the University of Notre Dame and a J.D. from Catholic University of America.

Stuart Paul


Stuart Paul has served as our President and Chief Executive Officer and a member of Rockwell Medical’s Board of Directors since September 2018.

Mr. Paul has significant operating experience in the healthcare industry, with a successful track record of executing commercialization strategies both domestically and internationally throughout his 25-year career. Previously, Mr. Paul served as Corporate Officer and Vice President of Abbott Laboratories, where he facilitated integration of the Alere acquisition, while leading its largest global business unit with $600 million of revenues. From 2015 to 2017, Mr. Paul served as the Vice President and General Manager of Quest Diagnostics’ U.S. East Region, where he led the turnaround of laboratories, patient services and the commercial business.

From 2007 to 2013, Mr. Paul worked within private equity at Gambro AB, where he was responsible for leading and profitably expanding a variety of businesses, including its Asia-Pacific and Americas Renal therapeutics businesses. Following the successful exit and sale of Gambro AB to Baxter International, Mr. Paul led the integration of the combined Baxter-Gambro Renal business in Latin America, driving further synergies, revenue and profit growth.

Mr. Paul received his bachelor’s degree in chemistry from Duke University and his master’s in marketing and finance from the Kellogg School of Management at Northwestern University.

Robert S. Radie


Robert Radie has served as a Director on our Board since March 2020.

Mr. Radie has more than three decades of industry experience, working in both public and private pharmaceutical and biotech companies across a range of therapeutic areas. He has held senior executive positions in several companies, including serving as Chief Executive Officer of Zyla Life Sciences, Topaz Pharmaceuticals, Inc., and Transmolecular, Inc. Mr. Radie also served as Chief Business Officer at Prestwick Pharmaceuticals, Inc., Morphotek, Inc., and Senior Vice President of Strategy and Planning at Vicuron Pharmaceuticals, Inc. Mr. Radie began his career at Eli Lilly and Company, where he worked for 18 years in sales and marketing positions with increasing levels of responsibility.

Mr. Radie holds several Board positions, including Paratek Pharmaceuticals, a public biopharmaceutical company; LPSA, the Pennsylvania industry advocacy group; and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. He previously served on the Boards of Veloxis Pharmaceuticals and Affinium Pharmaceuticals, a private specialty pharmaceutical company.

Mr. Radie received his B.S. in Chemistry from Boston College.

Mark Ravich


Mark Ravich has served as a Director on our Board since June 2017.

Mr. Ravich is the President of Tri-Star Management, which he co-founded in 1998. Additionally, he serves as the chief manager of various real estate entities. He is also a Director of Dilion Technologies and Orchids Paper Products Company, where he serves as Chairman of its Governance Committee and a Member of its Audit Committee. Previously, from 1990 until its sale in 1998, Mr. Ravich served as the Chief Executive Officer and a Director of Universal International.

Mr. Ravich received his BSE and MBA, Magna Cum Laude, from the Wharton School of the University of Pennsylvania.